Chimeric Therapeutics Limited TempASX: CHMDA

CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi

Apr 27, 2026 at 3:36 AM UTC · Issued by Chimeric Therapeutics Limited Temp

Chimeric Therapeutics Limited Temp has released a press release.

View Attachment